Finasteride treatment of female pattern hair loss

Matilde Iorizzo, Colombina Vincenzi, Stylianos Voudouris, Bianca Maria Piraccini, Antonella Tosti

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of oral finasteride therapy associated with an oral contraceptive containing drospirenone and ethinyl estradiol in premenopausal women with female pattern hair loss. Setting: Outpatient consultation for hair disorders at the Department of Dermatology, University of Bologna. Patients and Intervention: Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2.5 mg/d, while taking an oral contraceptive containing drospirenone and ethinyl estradiol. Treatment efficacy was evaluated using global photography and the hair density score from videodermoscopy. A self-administered questionnaire was used to assess patient evaluation of treatment effectiveness. Results: At 12-month follow-up, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved, and 3 were greatly improved). No improvement was recorded in 13 patients. One patient experienced worsening of the condition. There was a statistically significant (P=.002) increase in the hair density score in 12 patients. No adverse reactions to the drug were reported. Conclusions: Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive. It is unclear whether the success was due to a higher dosage of finasteride (2.5 mg instead of 1 mg) or to its association with the oral contraceptive containing drospirenone, which has an antiandrogenic effect. Further studies are necessary to understand which patterns of female pattern hair loss respond better to this treatment.

Original languageEnglish
Pages (from-to)298-302
Number of pages5
JournalArchives of Dermatology
Volume142
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Finasteride
Alopecia
Oral Contraceptives
Hair
Ethinyl Estradiol
Photography
Therapeutics
Dermatology
Drug-Related Side Effects and Adverse Reactions
Outpatients
Referral and Consultation

ASJC Scopus subject areas

  • Dermatology

Cite this

Iorizzo, M., Vincenzi, C., Voudouris, S., Piraccini, B. M., & Tosti, A. (2006). Finasteride treatment of female pattern hair loss. Archives of Dermatology, 142(3), 298-302. https://doi.org/10.1001/archderm.142.3.298

Finasteride treatment of female pattern hair loss. / Iorizzo, Matilde; Vincenzi, Colombina; Voudouris, Stylianos; Piraccini, Bianca Maria; Tosti, Antonella.

In: Archives of Dermatology, Vol. 142, No. 3, 01.03.2006, p. 298-302.

Research output: Contribution to journalArticle

Iorizzo, M, Vincenzi, C, Voudouris, S, Piraccini, BM & Tosti, A 2006, 'Finasteride treatment of female pattern hair loss', Archives of Dermatology, vol. 142, no. 3, pp. 298-302. https://doi.org/10.1001/archderm.142.3.298
Iorizzo, Matilde ; Vincenzi, Colombina ; Voudouris, Stylianos ; Piraccini, Bianca Maria ; Tosti, Antonella. / Finasteride treatment of female pattern hair loss. In: Archives of Dermatology. 2006 ; Vol. 142, No. 3. pp. 298-302.
@article{274d6de7ef5443388ca83781fe212e0e,
title = "Finasteride treatment of female pattern hair loss",
abstract = "Objective: To evaluate the efficacy of oral finasteride therapy associated with an oral contraceptive containing drospirenone and ethinyl estradiol in premenopausal women with female pattern hair loss. Setting: Outpatient consultation for hair disorders at the Department of Dermatology, University of Bologna. Patients and Intervention: Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2.5 mg/d, while taking an oral contraceptive containing drospirenone and ethinyl estradiol. Treatment efficacy was evaluated using global photography and the hair density score from videodermoscopy. A self-administered questionnaire was used to assess patient evaluation of treatment effectiveness. Results: At 12-month follow-up, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved, and 3 were greatly improved). No improvement was recorded in 13 patients. One patient experienced worsening of the condition. There was a statistically significant (P=.002) increase in the hair density score in 12 patients. No adverse reactions to the drug were reported. Conclusions: Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive. It is unclear whether the success was due to a higher dosage of finasteride (2.5 mg instead of 1 mg) or to its association with the oral contraceptive containing drospirenone, which has an antiandrogenic effect. Further studies are necessary to understand which patterns of female pattern hair loss respond better to this treatment.",
author = "Matilde Iorizzo and Colombina Vincenzi and Stylianos Voudouris and Piraccini, {Bianca Maria} and Antonella Tosti",
year = "2006",
month = "3",
day = "1",
doi = "10.1001/archderm.142.3.298",
language = "English",
volume = "142",
pages = "298--302",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Finasteride treatment of female pattern hair loss

AU - Iorizzo, Matilde

AU - Vincenzi, Colombina

AU - Voudouris, Stylianos

AU - Piraccini, Bianca Maria

AU - Tosti, Antonella

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Objective: To evaluate the efficacy of oral finasteride therapy associated with an oral contraceptive containing drospirenone and ethinyl estradiol in premenopausal women with female pattern hair loss. Setting: Outpatient consultation for hair disorders at the Department of Dermatology, University of Bologna. Patients and Intervention: Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2.5 mg/d, while taking an oral contraceptive containing drospirenone and ethinyl estradiol. Treatment efficacy was evaluated using global photography and the hair density score from videodermoscopy. A self-administered questionnaire was used to assess patient evaluation of treatment effectiveness. Results: At 12-month follow-up, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved, and 3 were greatly improved). No improvement was recorded in 13 patients. One patient experienced worsening of the condition. There was a statistically significant (P=.002) increase in the hair density score in 12 patients. No adverse reactions to the drug were reported. Conclusions: Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive. It is unclear whether the success was due to a higher dosage of finasteride (2.5 mg instead of 1 mg) or to its association with the oral contraceptive containing drospirenone, which has an antiandrogenic effect. Further studies are necessary to understand which patterns of female pattern hair loss respond better to this treatment.

AB - Objective: To evaluate the efficacy of oral finasteride therapy associated with an oral contraceptive containing drospirenone and ethinyl estradiol in premenopausal women with female pattern hair loss. Setting: Outpatient consultation for hair disorders at the Department of Dermatology, University of Bologna. Patients and Intervention: Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2.5 mg/d, while taking an oral contraceptive containing drospirenone and ethinyl estradiol. Treatment efficacy was evaluated using global photography and the hair density score from videodermoscopy. A self-administered questionnaire was used to assess patient evaluation of treatment effectiveness. Results: At 12-month follow-up, 23 of the 37 patients were rated as improved using global photography (12 were slightly improved, 8 were moderately improved, and 3 were greatly improved). No improvement was recorded in 13 patients. One patient experienced worsening of the condition. There was a statistically significant (P=.002) increase in the hair density score in 12 patients. No adverse reactions to the drug were reported. Conclusions: Sixty-two percent of the patients demonstrated some improvement of their hair loss with the use of finasteride, 2.5 mg/d, while taking the oral contraceptive. It is unclear whether the success was due to a higher dosage of finasteride (2.5 mg instead of 1 mg) or to its association with the oral contraceptive containing drospirenone, which has an antiandrogenic effect. Further studies are necessary to understand which patterns of female pattern hair loss respond better to this treatment.

UR - http://www.scopus.com/inward/record.url?scp=33645110044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645110044&partnerID=8YFLogxK

U2 - 10.1001/archderm.142.3.298

DO - 10.1001/archderm.142.3.298

M3 - Article

C2 - 16549704

AN - SCOPUS:33645110044

VL - 142

SP - 298

EP - 302

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 3

ER -